Overview

HuMax-CD20 in Chronic Lymphocytic Leukemia

Status:
Withdrawn
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Chronic Lymphocytic Leukemia.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Antibodies, Monoclonal
Ofatumumab